Barrons.com15d agoneutral
Novo Nordisk Raises Earnings Guidance. The Stock Sinks.The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
241last 24h
1433last 7d
241● bullish (7d)
157● bearish (7d)
205publishers
GuruFocus.com15d agoneutral
Lilly Opens Pre-Approval Access to Its Next Obesity DrugLilly plans to file for FDA approval in the first quarter of next year
Investor's Business Daily15d agobearish
Novo Nordisk Dives 6% After Unexpectedly Releasing Earnings A Day EarlyNovo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.
Insider Monkey15d agoneutral
Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market?Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Zacks16d agoneutral
Pfizer (PFE) Q2 Earnings and Revenues Top EstimatesPfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Barrons.com16d agoneutral
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are OpenEven if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Motley Fool16d agobullish
Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?Eli Lilly's key catalyst for 2027 could positively affect price action sooner than you think.
Investopedia16d agoneutral
Here’s How Much Traders See Eli Lilly Stock Moving After EarningsEli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker’s stock could potentially approach last month’s highs following the results.
Bloomberg16d agobullish
Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally(Bloomberg) -- Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.Most Read from BloombergBeer Dynasty Families Sell €731 Million Stake in AB InBevApple’s New CEO Taps Retired Hardware Executive for Management TeamTaco Bell Met With Michigan on Parasite Weeks Before RecallMamdani Dismisses Business Leaders Advising NYC’s Mayor’s FundS&P 5
Pharma Voice16d agoneutral
Three potential takeover targets in psychedelicsLilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.
The Wall Street Journal16d agoneutral
SpaceX Earnings, Jobs Numbers: What to Watch This WeekToday Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
Barrons.com16d agoneutral
More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or NotEven if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Proactive16d agoneutral
Amplia Therapeutics partners with Lilly on lung cancer combination trialAmplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF) has signed a clinical collaboration agreement with Eli Lilly and Company to evaluate its lead drug narmafotinib alongside Lilly’s next-generation KRAS G12C inhibitor olomorasib in patients with advanced non-small cell lung cancer (NSCLC). The...
MarketBeat16d agoneutral
Inspire Medical Systems Q2 Earnings Call HighlightsInspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting
Simply Wall St.16d agobullish
Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Backs $70 Million RaiseThe FDA granted Breakthrough Therapy designation to Eli Lilly's olomorasib as a monotherapy for KRAS G12C-mutant advanced pancreatic cancer. This is the second Breakthrough Therapy designation for olomorasib, which targets a patient group with limited treatment options. Ratio Therapeutics raised US$70 million in a Series C round that included participation from Eli Lilly. Eli Lilly, traded as NYSE:LLY, has long been known for its focus on oncology, diabetes and immunology. The latest...
Motley Fool16d agoneutral
Is Eli Lilly Stock Running out of Steam?The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion.
GuruFocus.com16d agoneutral
Eli Lilly's Latest Cancer Win Comes With a Big CaveatEarly data could widen Lilly's growth story beyond incretins
24/7 Wall St.16d agoneutral
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.
Investor's Business Daily16d agoneutral
Read Between These Lines As Eli Lilly, Hot IPO And More Face Key TestAs stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.
PA Media: Money16d agoneutral
Stocks mixed as AstraZeneca merger talk dents FTSE 100The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
Zacks16d agoneutral
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.
Zacks16d agoneutral
Will Mounjaro & Zepbound Drive Lilly's Q2 Results: Buy, Sell or Hold?LLY is set to report Q2 results on Aug. 5, with GLP-1 drugs expected to drive growth as investors watch Foundayo's early sales.
Stocktwits17d agobullish
Eli Lilly’s Olomorasib Secures Second FDA Breakthrough Designation For Cancer Therapy – Retail Expects LLY Stock To Hit Record High SoonThe U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Lilly’s drug for advanced pancreatic cancer.